Bisphosphonates in metastatic prostate cancer.
作者信息
Khan Masood A, Partin Alan W
出版信息
Rev Urol. 2003 Summer;5(3):204-6.
Abstract
摘要
相似文献
1
Bisphosphonates in metastatic prostate cancer.双膦酸盐在转移性前列腺癌中的应用
Rev Urol. 2003 Summer;5(3):204-6.
2
The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates.
Semin Nucl Med. 2001 Jan;31(1):62-8. doi: 10.1053/snuc.2001.18767.
3
Bisphosphonates for advanced prostate cancer.双膦酸盐用于晚期前列腺癌。
Cochrane Database Syst Rev. 2006 Oct 18(4):CD006250. doi: 10.1002/14651858.CD006250.
4
Bisphosphonates to prevent skeletal complications in men with metastatic prostate cancer.
J Urol. 2003 Dec;170(6 Pt 2):S55-7; discussion S57-8. doi: 10.1097/01.ju.0000095102.34708.bc.
5
Utilization of bone densitometry for prediction and administration of bisphosphonates to prevent osteoporosis in patients with prostate cancer without bone metastases receiving antiandrogen therapy.利用骨密度测定法预测并给予双膦酸盐类药物，以预防接受抗雄激素治疗且无骨转移的前列腺癌患者发生骨质疏松。
Cancer Manag Res. 2014 Dec 24;7:13-8. doi: 10.2147/CMAR.S74116. eCollection 2015.
6
The role of bisphosphonates in the treatment of prostate cancer: recommendations from an expert panel.双膦酸盐在前列腺癌治疗中的作用：专家小组的建议。
Clin Genitourin Cancer. 2006 Mar;4(4):257-62. doi: 10.3816/CGC.2006.n.004.
7
Metabolic bone disease induced by prostate cancer: rationale for the use of bisphosphonates.前列腺癌诱发的代谢性骨病：使用双膦酸盐的理论依据。
J Urol. 2001 Dec;166(6):2023-31.
8
Bisphosphonates in the management of prostate carcinoma metastatic to the skeleton.
Cancer. 2000 Jun 15;88(12 Suppl):3047-53. doi: 10.1002/1097-0142(20000615)88:12+<3047::aid-cncr22>3.3.co;2-l.
9
Effect of bisphosphonates on overall survival in subgroups of patients with prostate cancer.双膦酸盐对前列腺癌患者亚组总生存的影响。
Clin Exp Metastasis. 2019 Jun;36(3):199-209. doi: 10.1007/s10585-019-09963-4. Epub 2019 Apr 8.
10
The role of bisphosphonates in the management of metastatic prostate cancer.双膦酸盐在转移性前列腺癌治疗中的作用。
Curr Oncol Rep. 2003 May;5(3):245-9. doi: 10.1007/s11912-003-0117-4.
引用本文的文献
1
Prostate cancer bone metastases biology and clinical management (Review).前列腺癌骨转移的生物学与临床管理（综述）
Oncol Lett. 2023 Mar 8;25(4):163. doi: 10.3892/ol.2023.13749. eCollection 2023 Apr.
2
Bisphosphonate-Based Conjugates and Derivatives as Potential Therapeutic Agents in Osteoporosis, Bone Cancer and Metastatic Bone Cancer.基于双膦酸盐的缀合物和衍生物作为骨质疏松症、骨癌和转移性骨癌治疗药物的潜力。
Int J Mol Sci. 2021 Jun 26;22(13):6869. doi: 10.3390/ijms22136869.
3
Bone metastases in biliary cancers: A multicenter retrospective survey.胆管癌骨转移：一项多中心回顾性调查。
J Bone Oncol. 2018 Apr 7;12:33-37. doi: 10.1016/j.jbo.2017.11.006. eCollection 2018 Sep.
4
The Effect of Bisphosphonates on Bone Mineral Density in Metastatic Prostate Cancer Patients Who Are Treated with Anti-Androgen Drugs and Radiotherapy.双膦酸盐类药物对接受抗雄激素药物和放射治疗的转移性前列腺癌患者骨密度的影响。
Curr Urol. 2014 Oct;7(4):181-4. doi: 10.1159/000365672. Epub 2014 Aug 20.
本文引用的文献
1
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.唑来膦酸治疗激素难治性转移性前列腺癌患者的一项随机、安慰剂对照试验。
J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. doi: 10.1093/jnci/94.19.1458.
2
The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.PLACORHEN研究：一项针对伴有疼痛性骨转移的激素抵抗性前列腺癌患者，使用（186）铼-依替膦酸盐进行的双盲、安慰剂对照、随机放射性核素研究。安慰剂对照铼研究。
J Nucl Med. 2002 Sep;43(9):1150-6.
3
Bisphosphonates in multiple myeloma.双膦酸盐在多发性骨髓瘤中的应用
Cochrane Database Syst Rev. 2002(3):CD003188. doi: 10.1002/14651858.CD003188.
4
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.高活性铼-186 羟基乙叉二膦酸盐联合自体外周血干细胞解救：一项针对骨转移的进展期激素难治性前列腺癌的 I 期研究。
Br J Cancer. 2002 Jun 5;86(11):1715-20. doi: 10.1038/sj.bjc.6600348.
5
The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma.前列腺癌患者骨转移的自然病史、骨骼并发症及治疗
Cancer. 2000 Jun 15;88(12 Suppl):2989-94. doi: 10.1002/1097-0142(20000615)88:12+<2989::aid-cncr14>3.3.co;2-h.
6
Markers of bone turnover for the management of patients with bone metastases from prostate cancer.用于前列腺癌骨转移患者管理的骨转换标志物。
Br J Cancer. 2000 Feb;82(4):858-64. doi: 10.1054/bjoc.1999.1012.
7
Optimal hormonal therapy for advanced prostatic carcinoma.晚期前列腺癌的最佳激素治疗
Semin Oncol. 1999 Apr;26(2):162-73.
8
9
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.帕米膦酸盐在降低乳腺癌伴溶骨性骨转移患者骨骼并发症方面的疗效。方案19阿仑膦酸钠乳腺癌研究组
N Engl J Med. 1996 Dec 12;335(24):1785-91. doi: 10.1056/NEJM199612123352401.
10
Bone metastases: improving the therapeutic index.骨转移：提高治疗指数。
Semin Oncol. 1994 Oct;21(5):630-56.
Zotero 插件